Data gathered: May 30
AI Stock Analysis - Dynavax Technologies (DVAX)
Analysis generated May 26, 2024. Powered by Chat GPT.
Dynavax Technologies Corporation (DVAX) operates as a biopharmaceutical company focused on leveraging the innate immune system to fight disease. The company develops and commercializes novel vaccines and immune-oncology therapies. Key products include Heplisav-B, a vaccine for hepatitis B, and several other programs in clinical and preclinical development aimed at addressing infectious diseases and cancer.
Stock Alerts - Dynavax Technologies (DVAX)
 |
Dynavax Technologies | May 12 Price is up by 7.1% in the last 24h. |
|
Dynavax Technologies | May 7 Price is down by -7.1% in the last 24h. |
|
Dynavax Technologies | April 16 Price is down by -7.1% in the last 24h. |
|
Dynavax Technologies | April 10 Price is down by -5.1% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Dynavax Technologies
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 2 | Sign up | Sign up | Sign up |
| Sentiment | 100 | Sign up | Sign up | Sign up |
| Webpage traffic | 5,000 | Sign up | Sign up | Sign up |
| Employee Rating | 74 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 12 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 18,981 | Sign up | Sign up | Sign up |
| Twitter Followers | 790 | Sign up | Sign up | Sign up |
| Twitter Mentions | N/A | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $33,000 | Sign up | Sign up | Sign up |
| Business Outlook | 59 | Sign up | Sign up | Sign up |
| Linkedin Employees | 342 | Sign up | Sign up | Sign up |
About Dynavax Technologies
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States.
| Price | $9.74 |
| Target Price | Sign up |
| Volume | 173,680 |
| Market Cap | $1.17B |
| Year Range | $9.4 - $14.4 |
| Dividend Yield | 0% |
| PE Ratio | 58.75 |
| Analyst Rating | 100% buy |
| Industry | Drug Manufacturers |
In the news
 |
Two Sigma Advisers LP Sells 30,600 Shares of Dynavax Technologies Co. (NASDAQ:DVAX)May 30 - ETF Daily News |
|
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Position in Dynavax Technologies Co. (NASDAQ:DVAX)May 26 - ETF Daily News |
|
Dynavax Technologies Co. (NASDAQ:DVAX) Stock Holdings Boosted by Deutsche Bank AGMay 25 - ETF Daily News |
|
Gotham Asset Management LLC Decreases Position in Dynavax Technologies Co. (NASDAQ:DVAX)May 22 - ETF Daily News |
 |
Dynavax Technologies: Hepatitis-B Vaccine Specialist Looking GoodMay 21 - SeekingAlpha |
Deep Track Capital Issues Letter to Fellow Dynavax Technologies Shareholders Detailing Critical Issues in Advance of Annual MeetingMay 15 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 68M | 14M | 54M | -96M | -94M | -0.009 |
| Q4 '24 | 72M | 13M | 59M | 7.1M | 11M | 0.050 |
| Q3 '24 | 81M | 13M | 68M | 18M | 10M | 0.120 |
| Q2 '24 | 74M | 12M | 62M | 11M | 19M | 0.080 |
| Q1 '24 | 51M | 11M | 40M | -8.7M | -7.9M | -0.070 |
Insider Transactions View All
| Novack David F filed to sell 8,078 shares at $14. March 26 '25 |
| Novack David F filed to sell 8,078 shares at $13.6. March 20 '25 |
| Novack David F filed to sell 22,098 shares at $14.4. March 10 '25 |
| CANO FRANCIS filed to sell 36,905 shares at $11.9. June 3 '24 |
| Burgess Justin filed to sell 13,425 shares at $12.8. March 4 '24 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$154.28 0.5% | 49 |
 |
Eli Lilly and CompanyLLY |
$732.5 1.4% | 69 |
 |
PfizerPFE |
$23.47 0.1% | 44 |
 |
AstrazenecaAZN |
$71.57 1% | 51 |
 |
AbbVieABBV |
$185.44 0.1% | 49 |
Read more about Dynavax Technologies (DVAX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, 4chan mentions, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Dynavax Technologies?
The Market Cap of Dynavax Technologies is $1.17B.
What is Dynavax Technologies' PE Ratio?
As of today, Dynavax Technologies' PE (Price to Earnings) ratio is 58.75.
What is the current stock price of Dynavax Technologies?
Currently, the price of one share of Dynavax Technologies stock is $9.74.
How can I analyze the DVAX stock price chart for investment decisions?
The DVAX stock price chart above provides a comprehensive visual representation of Dynavax Technologies' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Dynavax Technologies shares. Our platform offers an up-to-date DVAX stock price chart, along with technical data analysis and alternative data insights.
Does DVAX offer dividends to its shareholders?
As of our latest update, Dynavax Technologies (DVAX) does not offer dividends to its shareholders. Investors interested in Dynavax Technologies should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Dynavax Technologies?
Some of the similar stocks of Dynavax Technologies are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
.